Funding contributions & risk

Example 17 — Pharma transfer to an affiliate without research capability

Annex I · Example 17 · ¶59–63

OECD Guidelines 2022
At a glance
Company A transfers Product M (a candidate Alzheimer's compound) and the related intangibles to Company S. Company S has no R&D capability and immediately contracts the research back to Company A, paying cost-plus margins based on independent CROs. Are those CRO margins really the right benchmark?
Company A
Integrated pharma · runs R&D · controls Product M risks
IP rights ← · contract-research fee
Company S
Legal owner of Product M IP · no technical staff
  1. Company A is an integrated pharma that regularly hires independent CROs for clinical trials under its own active supervision.
  2. Company A transfers Product M patents and related intangibles to Company S; price is based on projected cash flows.
  3. Company S has no technical personnel; it contracts the research back to Company A.
  4. Company S agrees to fund the research and assume financial risk, paying Company A cost-plus margins benchmarked to independent CROs.

Company A still runs and controls the R&D. Company S can't actually manage research risk — it has no technical staff.

Are independent CRO margins really the right benchmark for what Company A does for Company S?

OECD analysis · Financing return only
Company A continues to perform and control functions and to manage risks related to the Product M intangibles, including the important functions in paragraph 6.56. The CRO arrangements are not comparable because the CROs do not have ongoing interests or control over research risk. On a thorough examination, the transaction should be delineated as the provision of financing by Company S; Company S is entitled to a financing return whose level depends on its control over financing risk. Company A is entitled to the remaining income or losses.
Key takeaway
A label of 'contract research' does not unlock CRO-level pricing. Where the funder cannot control research risk, the substance is financing — and the financing return goes with the financing risk it actually controls.

Related: Paragraph 6.56 (important functions) · Example 16 (parallel financing-return analysis) · Example 14 (true contract R&D, with control retained at the parent)

Test yourself on this example.Open it in the interactive walkthrough →